Skip to Content

Argos Therapeutics Inc. (NASDAQ: ARGS)

Securities Class Action

Overview
  • Date:
  • 3/23/2017
  • Company Name:
  • Argos Therapeutics Inc.
  • Stock Symbol:
  • ARGS
  • Class Period:
  • FROM 2/4/2014 TO 2/21/2017
  • Status:
  • Closed/Complete
  • Court:
  • U.S. District Court: Middle District of North Carolina

Case Finder

Locate any case using the tools below.

Bragar Eagel & Squire, P.C. announces that a class action lawsuit has been filed in the United States District Court for the Middle District of North Carolina on behalf of all persons or entities who acquired Argos Therapeutics Inc. (NASDAQ: ARGS) securities between February 4, 2014 and February 21, 2017 (the “Class Period”).

Argos focuses on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases in North America. Argos's most advanced product candidate, known as AGS-003, is designed to treat metastatic renal cell carcinoma ("mRCC") and other cancers.

According to the filed Complaint, in January 2013, Argos initiated an ADAPT Phase 3 clinical trial to evaluate AGS-003 for the treatment of mRCC. Argos subsequently issued a press release stating that its Phase 2 trial for AGS-003 showed a statistically significant correlation between the magnitude of the immune response and overall survival and that AGS-003 was the only drug the Company was aware of to show this effect with statistical significance. Argos continued to portray a positive outlook for AGS-003, stating that the Company was pleased with the progress of the Phase 3 trial and that Argos was well positioned to continue to develop the drug.

The Complaint alleges that Argos officials failed to disclose that its Arcentis technology platform was not viable and that ADAPT was likely to be discontinued. On February 22, 2017, Argos filed a Form 8-K with the US SEC revealing that the Independent Data Monitoring Committee for ADAPT recommended that the study be discontinued for futility, finding that the study was unlikely to show a statistically significant improvement in overall survival. The Company further revealed that it would discuss the data with the US FDA and based on those discussions, it will make a determination as to the next steps for the clinical program.

If you purchased or otherwise acquired Argos securities during the Class Period and suffered a loss or continue to hold shares purchased prior to the Class Period, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Melissa A. Fortunato, Esq. by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.

Case Finder

Locate any case using the tools below.

You may share a link to this page on any of the sites listed below or send link via email: